Apr 12, 2018

April 12, 2018 – Adynxx Inc., a clinical stage biotechnology company developing a novel platform of first-in-class, disease-modifying, non-opioid pain therapeutics, today announced Phase 2 study results of its lead therapeutic candidate, brivoligide (AYX1) for the treatment of post-surgical pain. The ADYX-004 trial assessed safety and efficacy of a single preoperative dose of brivoligide compared to placebo in 210 subjects undergoing unilateral total knee arthroplasty where all subjects also received standard perioperative pain management.


Single intrathecal administration of the transcription factor decoy AYX1 prevents acute and chronic pain after incisional, inflammatory, or neuropathic injury.
Pharmacology, pharmacokinetics, and metabolism of the DNA-decoy AYX1 for the prevention of acute and chronic post-surgical pain.
Editor's Highlight: Formulation and Toxicology Evaluation of the Intrathecal AYX1 DNA-Decoy in Sprague Dawley Rats.
Intrathecal administration of AYX2 DNA-decoy produces a long-term pain treatment in rat models of chronic pain by inhibiting the KLF6, KLF9 and KLF15 transcription factors.